{
  "id": "5e33916afbd6abf43b000061",
  "type": "yesno",
  "question": "Does radiotherapy for prostate cancer increase bladder cancer risk?",
  "ideal_answer": "Yes, radiotherapy for prostate cancer is associated with increased bladder cancer risk.",
  "documents": [
    "http://www.ncbi.nlm.nih.gov/pubmed/27432454",
    "http://www.ncbi.nlm.nih.gov/pubmed/28499661",
    "http://www.ncbi.nlm.nih.gov/pubmed/25900243",
    "http://www.ncbi.nlm.nih.gov/pubmed/19553822",
    "http://www.ncbi.nlm.nih.gov/pubmed/27844130",
    "http://www.ncbi.nlm.nih.gov/pubmed/27370205",
    "http://www.ncbi.nlm.nih.gov/pubmed/26936410",
    "http://www.ncbi.nlm.nih.gov/pubmed/18801517",
    "http://www.ncbi.nlm.nih.gov/pubmed/27629559",
    "http://www.ncbi.nlm.nih.gov/pubmed/30293908"
  ],
  "snippets": [
    {
      "text": "External Beam Radiotherapy Increases the Risk of Bladder Cancer When Compared with Radical Prostatectomy in Patients Affected by Prostate Cancer: A Population-based Analysis.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30293908",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "On multivariable competing risk regression analyses, treatment with EBRT was independently associated with the risk of developing a second primary BCa (hazard ratio: 1.35, CI: 1.18-1.55; p<0.001), but not RCa (p=0.4). ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30293908",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "CONCLUSIONS: Patients treated with EBRT are at increased risk of developing a second primary BCa compared with those treated with RP. However, no differences were found considering RCa incidence in patients treated with RP or EBRT within the first 5 yr after primary therapy. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30293908",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "We found that those treated with external beam radiotherapy are at an increased risk of developing a second primary bladder cancer tumor.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30293908",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "All radiation modalities were found to have an increased RR of developing BlCa after 10\u00a0years, with brachytherapy having a significantly higher RR than external beam radiation (EBRT) or combined EBRT and brachytherapy in Caucasian men and a significantly higher RR than EBRT in men of other/unknown ethnicity. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27629559",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "CONCLUSIONS: The increased risk of BlCa after prostate radiation occurs predominantly after 10\u00a0years, regardless of ethnicity. The RR of developing BlCa after 10\u00a0years is significantly higher following brachytherapy than after EBRT or EBRT and brachytherapy. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27629559",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Based on the data in the literature, there is a\u00a0consistently increased risk of bladder cancer (HR: 1.67, 95% CI 1.55-1.80), rectal cancer (HR: 1.79, 95% CI 1.34-2.38), and colorectal cancer (HR: 1.79, 95% CI 1.34-23.8) following percutaneous radiation therapy. Following brachytherapy only an increased for the development of bladder cancer (HR: 2.14, 95% CI 1.03-3.94) has been observed.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27844130",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "When comparing with a matched general French population, the standard incidence ratio (SIR) for bladder cancer was 1.02 (95% CI: 0.46-1.93).",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28499661",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "LDR resulted in lower bladder cancer risks than HDR, and lower or similar risks of rectal cancer.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27370205",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Compared to external beam techniques, second rectal and bladder cancer risks were lowest for brachytherapy.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27370205",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "OBJECTIVE: Although it is well known that radiotherapy for prostate cancer increases comorbid rate of secondary bladder cancer, the effect of aging and smoking with radiotherapy on incidence rate of secondary bladder cancer remains unknown. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27432454",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "RESULTS: During the median follow-up period of 4.3 and 3.1 years, secondary bladder cancer occurred in 11 (3.4%) and 5 (1.1%) of patients with prostate cancer treated with external beam radiotherapy and radical prostatectomy, respectively. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27432454",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "CONCLUSIONS\n\nMen who receive radiotherapy for localized prostate cancer have an increased risk of bladder cancer compared to patients undergoing radical prostatectomy and compared to the general population.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/18801517",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Radiation therapy for prostate cancer increases subsequent risk of bladder and rectal cancer: a population based cohort study.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/18801517",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "RESULTS\n\nThe relative risk of bladder cancer developing after external beam radiotherapy, brachytherapy and external beam radiotherapy-brachytherapy compared to radical prostatectomy was 1.88, 1.52 and 1.85, respectively.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/18801517",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Compared to the general United States population the standardized incidence ratio for bladder cancer developing after radical prostatectomy, external beam radiotherapy, brachytherapy and external beam radiotherapy-brachytherapy was 0.99, 1.42, 1.10 and 1.39, respectively.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/18801517",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "OBJECTIVE\n\nAlthough it is well known that radiotherapy for prostate cancer increases comorbid rate of secondary bladder cancer, the effect of aging and smoking with radiotherapy on incidence rate of secondary bladder cancer remains unknown.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27432454",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "OBJECTIVE\nAlthough it is well known that radiotherapy for prostate cancer increases comorbid rate of secondary bladder cancer, the effect of aging and smoking with radiotherapy on incidence rate of secondary bladder cancer remains unknown.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27432454",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "CONCLUSIONS\nMen who receive radiotherapy for localized prostate cancer have an increased risk of bladder cancer compared to patients undergoing radical prostatectomy and compared to the general population.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/18801517",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "PURPOSE\nPre-prostate specific antigen era series demonstrated an increased risk of bladder cancer and rectal cancer in men who received radiotherapy for prostate cancer.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/18801517",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "RESULTS\nThe relative risk of bladder cancer developing after external beam radiotherapy, brachytherapy and external beam radiotherapy-brachytherapy compared to radical prostatectomy was 1.88, 1.52 and 1.85, respectively.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/18801517",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "CONCLUSIONS: Taken together, these findings suggest that smoking history might be one of criteria to choose radical prostatectomy than external beam radiotherapy for prostate cancer, and that age would not be a criterion for therapeutic selection in terms of secondary bladder cancer.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27432454",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "PURPOSE: Pre-prostate specific antigen era series demonstrated an increased risk of bladder cancer and rectal cancer in men who received radiotherapy for prostate cancer.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/18801517",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "RESULTS: The relative risk of bladder cancer developing after external beam radiotherapy, brachytherapy and external beam radiotherapy-brachytherapy compared to radical prostatectomy was 1.88, 1.52 and 1.85, respectively.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/18801517",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Compared to the general United States population the standardized incidence ratio for bladder cancer developing after radical prostatectomy, external beam radiotherapy, brachytherapy and external beam radiotherapy-brachytherapy was 0.99, 1.42, 1.10 and 1.39, respectively.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/18801517",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Pre-prostate specific antigen era series demonstrated an increased risk of bladder cancer and rectal cancer in men who received radiotherapy for prostate cancer.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/18801517",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Men who receive radiotherapy for localized prostate cancer have an increased risk of bladder cancer compared to patients undergoing radical prostatectomy and compared to the general population.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/18801517",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "The relative risk of bladder cancer developing after external beam radiotherapy, brachytherapy and external beam radiotherapy-brachytherapy compared to radical prostatectomy was 1.88, 1.52 and 1.85, respectively.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/18801517",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Radiotherapy for prostate cancer is associated with an increased incidence of secondary bladder cancer (BC).",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/25900243",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Radiation therapy for prostate cancer is associated with an increased risk of bladder cancer.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/19553822",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Radiotherapy for prostate cancer was associated with higher risks of developing second malignancies of the bladder, colon, and rectum compared with patients unexposed to radiotherapy, but the reported absolute rates were low.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/26936410",
      "beginSection": "abstract",
      "endSection": "abstract"
    }
  ],
  "concepts": [],
  "exact_answer": "Yes"
}